NPPB and atrial fibrillation: In various publications, newly identified HM predictors for this category of patients are related to signs of comorbidity, clinical, biochemical, and hematological indicators of inflammatory response, metabolic status parameters, heart chamber volumes, atrial fibrillation, BNP, D-dimer, and etc. Due to the prevailing strategy of myocardial revascularization by means of PCI, the need to develop HM risk measurement tools after PCI is growing.